Demamed
ActiveSummary
Demamed has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €295,828 and a net result of €202,653. Equity has been growing by about 137% per year since 2023. The computed 12-month bankruptcy probability is 0.1% (very low).
Overview
Overview
Official details
Source: KBO- Status
- Active since 27-07-2023 Normal situation
- Activity
- “De uitoefening van de geneeskunde met specialisatie radiologie door de arts-aandeelhouder, met inachtneming van…” (deed in Dutch)From the articles, 15 activitiesNo NACE code in the KBO yet
- Establishment unit
- 2.348.051.977 9300 Aalst, since 27-07-2023
- Financial year end
- 31 December
- Peppol
- Reachable since 13-02-2024
Board and ownership
Board
- DEMAEREL Victor Gabriël Maria Rik Ingele Philippe BenediktDirector · since 27-07-2023
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.1%
Annual accounts 2025
- Gross margin
- €279,267
- ▲ 303%
- Turnover
- ≈ €560,000
- estimated
- Profit
- €202,653
- ▲ 286%
- Equity
- €295,828
- ▲ 217%
- Total assets
- €402,793
- ▲ 257%
Filed on 30-06-2026, 31 days before the deadline
Score breakdownraises riskFounded in 2023lowers riskSize: total assets €402,793Liquidity: current ratio 4.53, cash €152,038No main activity registeredShow the evidence
Checked score
Score 2025
98
/ 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 83% of micro companies without a NACE code
Financial strength · tick: 2024
Strong
Solvency
98-2
equity 73.4% of total assets
Liquidity
92-3
short-term debt 18.2% · cash 37.7%
Profitability
100=
return on assets 50.3%
Bankruptcy probability within 12 months
0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.4%
01-2025: 0.4%● unchanged vs 12-2024
02-2025: 0.4%● unchanged vs 01-2025
03-2025: 0.4%● unchanged vs 02-2025
04-2025: 0.4%● unchanged vs 03-2025
05-2025: 0.5%▲ +0.1 percentage points vs 04-2025
06-2025: 0.5%● unchanged vs 05-2025
07-2025: 0.5%● unchanged vs 06-2025highest value
08-2025: 0.2%▼ -0.3 percentage points vs 07-2025
09-2025: 0.2%● unchanged vs 08-2025
10-2025: 0.2%● unchanged vs 09-2025
11-2025: 0.2%● unchanged vs 10-2025
12-2025: 0.2%● unchanged vs 11-2025
01-2026: 0.2%● unchanged vs 12-2025
02-2026: 0.2%● unchanged vs 01-2026
03-2026: 0.2%● unchanged vs 02-2026
04-2026: 0.2%● unchanged vs 03-2026
05-2026: 0.2%● unchanged vs 04-2026
06-2026: 0.2%● unchanged vs 05-2026
07-2026: 0.1%▼ -0.1 percentage points vs 06-2026lowest value
08-2026: 0.1%● unchanged vs 07-2026lowest value
09-2026: 0.1%● unchanged vs 08-2026lowest value
10-2026: 0.1%● unchanged vs 09-2026lowest value
11-2026: 0.1%● unchanged vs 10-2026lowest value
Credit of up to €25,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 4.53 (4.88 in 2024), above the usual 1.5. Short-term debt is 18.2% and cash 37.7% of total assets. 26.6% of the assets are financed with debt and provisions.
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (no NACE code, micro). It does better than 61% of them on solvency, 83% on liquidity, 90% on profitability and 96% on growth.
The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 30-06-2026, 31 days ahead of the deadline.
NBB · 3 filingsDeviation from the deadline
2025
31 days early
2024
7 days early
2023
6 days early
← before the deadline
after the deadline →
tick = median of all Belgian filings
The company filed its last 3 accounts on average 15 days before the deadline. The Belgian median for financial year 2024 was 4 days before the deadline, and 38% of all filings were late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 24 July (3 of the last 3 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
02-11-2026 today31-12-2026 year end31-07-2027 deadline
Financials
Financials · financial year 2025, micro format
Annual accounts 2025 filed on 30-06-2026 at the NBB all 3 filings
Turnover
≈ €560,000
Estimated: probably between €390,000 and €810,000
Total assets
€402,793▲ 257%
2024 · €112,747
Net result
€202,653▲ 286%
2024 · €52,563
Working capital
€258,007▲ 240%
2024 · €75,905
Trend over the years
2023 to 2025, 3 financial years
The operating result for 2025 is 4 times that of 2024 and the highest since 2023. It is the second rise in a row.
Operating result€265,274
2025
Net result€202,653
2025
Total assets€402,793
2025
Equity€295,828
2025
Debt€106,965
2025
Working capital€258,007
2025
Turnover is what the company sold, the result is what was left of it. A loss stands below the zero line.
Assets, equity and debt per financial year.
Above zero, the company can pay its short-term debts with what it holds in the short term.
Use the arrow keys on the chart for the figures per year.
Every figure with its change against the financial year before
favourable
unfavourable
Line202320242025
Operating result€52,537-€66,205▲ 26.0%€265,274▲ 301%
Net result€43,111-€52,563▲ 21.9%€202,653▲ 286%
Equity€40,611-€93,174▲ 129%€295,828▲ 217%
Total assets€54,465-€112,747▲ 107%€402,793▲ 257%
Debt€13,854-€19,573▲ 41.3%€106,965▲ 447%
Working capital€25,693-€75,905▲ 195%€258,007▲ 240%
Turnover and EBIT margin are not published. The micro format does not require them. The turnover shown is an estimate from the gross margin.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €402,793
Fixed assets
€71,634 ▲ 315%
Current assets
€331,159 ▲ 247%
Equity and liabilities €402,793
Equity
€295,828 ▲ 217%
Debt
€106,965 ▲ 447%
Debt's share of the balance-sheet total rises from 17.4% to 26.6%. Equity and debt are higher.
Key figures and ratios
EBITDA
€279,212▲
2024 · €69,225
Cash flow
€216,591▲
2024 · €55,583
Current ratio
4.53▼
2024 · 4.88
Debt to equity
0.36▲
2024 · 0.21
ROE
68.5%▲
2024 · 56.4%
ROA
50.3%▲
2024 · 46.6%
Interest coverage
over 100
2024 · over 100
Debt ≤ 1 year
€73,152▲
2024 · €19,573
Debt > 1 year
€33,813
Income taxes
€60,978▲
2024 · €13,565
Green means a favourable move, even when the figure itself falls, as with debt or debt to equity.
Investments
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Tangible fixed assets | €13,765 | €5,296 | €68,376 |
| Financial fixed assets | - | €75 | - |
| Depreciation and write-downs of the year | €1,509 | €3,019 | €13,937 |
Source: notes to the 2023 to 2025 annual accounts (statement of fixed assets)
Companies with the same profile, two years later
Historical observationIn July 2024, 39,278 companies had the same profile as Demamed has now. Two years later, 1.8% had gone bankrupt and 95.9% were still going.
- Micro
- 2 to 5 years old
- solvency 30% or more
- a profit of 5% of the balance sheet or more
1.8%
went bankrupt
2.3%
stopped otherwise
95.9%
was still going
The bankruptcy probability of Demamed itself is lower: 0.1% within 12 months. It rests on far more data about Demamed than the profile alone.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 39,278 companies, not a prediction for Demamed. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Annual accounts
| Line | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €1,509 | €3,019 | €13,937 | ▲ 362% |
| Other operating charges640/8 | - | €55 | €55 | = |
| Gross operating margin9900 | €54,046 | €69,280 | €279,267 | ▲ 303% |
| Operating profit (loss)9901 | €52,537 | €66,205 | €265,274 | ▲ 301% |
| Financial income75/76B | - | €1 | - | - |
| Recurring financial income75 | - | €1 | - | - |
| Financial charges65/66B | €13 | €78 | €1,643 | ▲ 21× |
| Recurring financial charges65 | €13 | €78 | €1,643 | ▲ 21× |
| Profit (loss) for the period before taxes9903 | €52,525 | €66,128 | €263,631 | ▲ 299% |
| Income taxes67/77 | €9,414 | €13,565 | €60,978 | ▲ 350% |
| Profit (loss) for the period9904 | €43,111 | €52,563 | €202,653 | ▲ 286% |
| Profit (loss) for the period to be appropriated9905 | €43,111 | €52,563 | €202,653 | ▲ 286% |
| Line | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|
| Assets | ||||
| Total assets20/58 | €54,465 | €112,747 | €402,793 | ▲ 257% |
| Formation expenses20 | €1,331 | - | - | - |
| Fixed assets21/28 | €13,587 | €17,270 | €71,634 | ▲ 315% |
| Tangible fixed assets22/27 | €13,587 | €17,195 | €71,634 | ▲ 317% |
| Land and buildings22 | €13,587 | €12,211 | €21,272 | ▲ 74.2% |
| Plant, machinery and equipment23 | - | - | €1,944 | - |
| Furniture and vehicles24 | - | €4,984 | €48,418 | ▲ 871% |
| Financial fixed assets28 | - | €75 | - | - |
| Current assets29/58 | €39,547 | €95,477 | €331,159 | ▲ 247% |
| Amounts receivable within one year40/41 | - | €3,636 | €176,764 | ▲ 49× |
| Trade receivables40 | - | - | €174,049 | - |
| Other amounts receivable41 | - | €3,636 | €2,715 | ▼ 25.3% |
| Cash at bank and in hand54/58 | €39,547 | €90,655 | €152,038 | ▲ 67.7% |
| Deferred charges and accrued income490/1 | - | €1,186 | €2,357 | ▲ 98.8% |
| Equity and liabilities | ||||
| Total equity and liabilities10/49 | €54,465 | €112,747 | €402,793 | ▲ 257% |
| Equity10/15 | €40,611 | €93,174 | €295,828 | ▲ 217% |
| Contributions10/11 | €2,500 | €2,500 | €2,500 | = |
| Profit (loss) carried forward14 | €38,111 | €90,674 | €293,328 | ▲ 223% |
| Amounts payable17/49 | €13,854 | €19,573 | €106,965 | ▲ 447% |
| Amounts payable after more than one year17 | - | - | €33,813 | - |
| Financial debts170/4 | - | - | €33,813 | - |
| Amounts payable within one year42/48 | €13,854 | €19,573 | €73,152 | ▲ 274% |
| Current portion of amounts payable after more than one year42 | - | - | €10,966 | - |
| Trade debts44 | €2,054 | €6,008 | €1,200 | ▼ 80.0% |
| Suppliers440/4 | €2,054 | €6,008 | €1,200 | ▼ 80.0% |
| Taxes, remuneration and social security45 | €9,414 | €13,565 | €60,986 | ▲ 350% |
| Taxes450/3 | €9,414 | €13,565 | €60,986 | ▲ 350% |
| Other amounts payable47/48 | €2,386 | - | - | - |
| Line | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|
| Profit (loss) for the period9904 | €43,111 | €52,563 | €202,653 | ▲ 286% |
| + Depreciation and write-downs630 | €1,509 | €3,019 | €13,937 | ▲ 362% |
| Operating cash flow (approximation) | €44,620 | €55,583 | €216,591 | ▲ 290% |
| Investment in fixed assets (approximation) | - | -€6,702 | -€68,301 | ▼ 919% |
| Change in cash | - | €51,108 | €61,383 | ▲ 20.1% |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Board & ownership
Directors
Directors
1 director, no change since 2023
DEMAEREL Victor Gabriël Maria Rik Ingele Philippe Benedikt
Current
Director (not named in the articles) · since 27-07-2023 · term without a fixed end · listed in the 2025 annual accounts, filed on 30-06-2026
Signing authorityThe articles say who may bind the company, for example by signing a contract.
“vergadering voorbehouden, met dien verstande dat de bestuurder die geen arts is enkel kan instaan voor niet-medische aangelegenheden en dat…”
deed of 31-07-2023Owners and capital
Shareholders
At incorporation
act of 31-07-2023 ↗
- DEMAEREL Victor Gabriël Maria Rik Ingele Philippe Benedikt 100 shares (100%)
Capital transactions
Capital over time
- 31-07-2023 Incorporation · €2,500 · 100 shares
Articles of association
Capital, shares and profit
- Kind of sharesThe articles set which classes of shares exist and what rights each class carries.
- “100, gelijk recht in winstverdeling”
- Membership ruleThe articles set who can become a member or partner, and on what terms.
- “Artsen ingeschreven op Lijst van de Orde van Artsen, aandelenbezit in verhouding tot respectievelijke activiteit”
Audit, dissolution and liquidation
- Liquidation ruleIn a liquidation the creditors are paid first. What is left goes to the shareholders.
- “Alle machten artikel 2:87 Wetboek van vennootschappen en verenigingen zonder bijzondere machtiging, een of meer vereffenaars door algemene…”
Articles of association, deed of 31-07-2023 (in Dutch)
Network & group
Demamed shares no director with another company.
Companies at the same address
1 other companyConnections & network
1 current directorThe network starts from the directors of Demamed. Every other company they run is a node.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Timeline
Acts, filings and financial milestones
Deadline for the 2026 accounts:
2026
30-06
micro format · 31 days before the deadline
2025
31-12
Financial
Highest result from 2023 to 2025net €202,653 ▲286%
The operating result of €265,274 and the net result of €202,653 are both a record.
31-12
Financial
Equity above €200,000equity €295,828 ▲217%
With a profit in every financial year since 2023, equity grows to €295,828.
24-07
micro format · 7 days before the deadline
2024
25-07
micro format · 6 days before the deadline
2023
31-07
Gazette deed
IncorporationStarting capital €2,500 · Appointment: DEMAEREL Victor Gabriël Maria Rik Ingele Philippe Benedikt (director) · Permanent representative: Dieter Schelpe · Founder7 points ▸
Gazette deed
Incorporation
Starting capital €2,500 · Appointment: DEMAEREL Victor Gabriël Maria Rik Ingele Philippe Benedikt (director) · Permanent representative: Dieter Schelpe · Founder7 points ▸
- Incorporation, 26-07-2023
- Founder, DEMAEREL Victor Gabriël Maria Rik Ingele Philippe Benedikt
- Founding capital, €2,500
- Bank account, “Belfius Bank, bijzondere rekening” (deed in Dutch)
- Director appointment, DEMAEREL Victor Gabriël Maria Rik Ingele Philippe Benedikt (director (not named in the articles))
- Permanent representative, Dieter Schelpe
- Director in office, Millemol CommV (director)
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Register details
Identity
KBO recordName
Demamed in Dutch
Enterprise number
0804.332.017
Legal form
Private limited company
Status
Active, normale toestand
Founded
27-07-2023
Entity type
Legal entity
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
deed of 31-07-2023 (in Dutch)Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
“Vlaamse Gewest, Bladerenkwartier 18,1730 Asse”
deed of 31-07-2023 (in Dutch)Registered office and establishments
Registered office
Bladerenkwartier 18, 1730 Asse, Belgium
Establishment unit
Demamed, Moorselbaan 164, 9300 Aalst since 27-07-2023 · unit number 2.348.051.97786220 Specialist medical practice
Activities
PurposeThe purpose describes the activities the company may carry out under its articles.
deed of 31-07-2023 (in Dutch)
“De uitoefening van de geneeskunde met specialisatie radiologie door de arts-aandeelhouder, met inachtneming van de regels van de medische…”
15 activities
- De uitoefening van de geneeskunde met specialisatie radiologie door de arts-aandeelhouder, met inachtneming van de regels van de medische deontologie. De aandeelhouder oefent zijn volledige medische activiteit uit in naam en voor rekening van de vennootschap. De professionele aansprakelijkheid van de arts-aandeelhouder is onbeperkt.
- Deze activiteiten worden uitgeoefend met eerbiediging van de deontologische en administratieve voorschriften, volgens de principes van de medische ethiek en de eisen van de wetenschappelijke discipline. Meer bepaald zal de vrije artsenkeuze in hoofde van de patiënt, de diagnostische en therapeutische vrijheid alsook het respect voor het medisch beroepsgeheim behouden blijven.
- De vennootschap waakt erover dat de onafhankelijkheid van de aandeelhouder in de uitoefening van zijn beroep gewaarborgd blijft en dat geen aanleiding ontstaat tot commerciële beoefening van de geneeskunde, tot directe of indirecte collusie, dichotomie of overconsumptie.
- Het inrichten van algemene diensten en een medisch secretariaat in het bijzonder, die nodig of nuttig zijn voor de uitoefening van voornoemde activiteiten;
- De aankoop, het huren, leasen en invoeren van alle medische apparatuur en begeleidende accommodaties, inclusief gebouwen en transportmiddelen, voor voornoemde activiteiten, kortom van een volledige materiële infrastructuur voor de praktijk van de arts-aandeelhouder;
- Het aanleggen van reserves, nodig tot het aanschaffen van alle dienstige apparatuur, gebouwen en transportmiddelen noodzakelijk en bevorderlijk voor het uitoefenen van alle bovenvermelde beroepsactiviteiten door de artsaandeelhouder;
- De mogelijkheid scheppen om de aandeelhouder toe te laten zich verder te bekwamen in voormelde medische disciplines, dit teneinde een kwalitatief hoogstaande praktijkuitoefening mogelijk te maken. Bovendien kan de vennootschap informatie verstrekken en of onderricht geven, zonder dat dit de vorm van een aanvullende commerciële activiteit mag aannemen.
- De vennootschap mag samenwerken met alle ondernemingen die een gelijkaardig voorwerp nastreven, maar overeenkomsten die artsen niet mogen afsluiten met andere artsen of met derden, zullen evenmin door de vennootschap mogen afgesloten worden. Aldus zal de vennootschap geen deelnemingen mogen bezitten van een andere artsenvennootschap waarbinnen een medische activiteit wordt uitgeoefend.
- De vennootschap kan deelnemen in kostenassociaties of middelenvennootschappen van artsen, of lid zijn van een vereniging zonder winstgevend doel van artsen.
- De vennootschap mag als bijkomstig voorwerp, beleggen in roerende of onroerende goederen, mits dit een beheren is van de roerende en onroerende goederen als een goede huisvader, en zonder dat dit op geen enkel ogenblik aanleiding mag geven tot het ontwikkelen van welke commerciële activiteit ook.
- Wanneer er meerdere aandeelhouders zijn, dienen de beslissingen in verband met het investeringsbeleid te gebeuren met unanimiteit van stemmen.
- Het beleggen of investeren van haar middelen mag gefinancierd worden door leningen.
- De vennootschap kan zowel tot waarborg van eigen verbintenissen als tot waarborg van verbintenissen van derden borg stellen, onder meer door haar goederen in hypotheek of in pand te geven, inclusief het eigen beroepsfonds.
- De vennootschap kan eveneens optreden als bestuurder, volmachtdrager of mandataris in andere vennootschappen of ondernemingen die hetzelfde voorwerp hebben als onderhavige vennootschap.
- De vennootschap zal in het algemeen alle burgerlijke, roerende of onroerende handelingen mogen verrichten in rechtstreeks verband met haar voorwerp of welke van die aard zouden zijn dat zij het bereiken ervan rechtstreeks, geheel of ten dele vergemakkelijken, dit alles rekening houdend met de medische deontologie ter zake.
Invoicing and payment
VAT number
BE 0804.332.017
Financial year and general meeting
Accounts at the NBBFinancial year end
31-12
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
Last Saturday of June at 18:00
deed of 31-07-2023 (in Dutch)Sites & property
Location
Buildings and parcels at the addresses
Ground area
6,687 m²
Building footprint
276 m²
Building volume
1,511 m³
Tallest building: 7.5 m.
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 23002A0066/00T000 | Flanders | 5,406 m² | 1 · 276 m² | 7.5 m · 2 |
| 41303E0485/00N000 | Flanders | 1,280 m² | - | - |